Global Hemoglobinopathies Market

Hemoglobinopathies Comprehensive Study by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease, Other Hb Variants Diseases), Application (Blood Testing, Genetic Testing, Pre-Implantation Genetic Diagnosis (PGD), Others), Therapy Type (Blood transfusion, Iron chelation therapy, Bone marrow transplant, Others), Test Type (Red Blood Cell (RBC) Count Test, Genetic Testing, Liquid Chromatography (HPLC) Test, Hemoglobin Isoelectric (Hb IEF) Focusing, Hemoglobin Electrophoresis (Hb ELP) Test, Hemoglobin Solubility Test), End User (Diagnostics Laboratories, Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2030

Hemoglobinopathies Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Hemoglobinopathies Market Overview:
The hemoglobinopathies are a group of disorders passed down through families (inherited) in which there is abnormal production or structure of the hemoglobin molecule. Sickle cell disease (SCD) is one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells. The abnormal red cells break down, causing anemia, and obstruct blood vessels, leading to recurrent episodes of severe pain and multi-organ ischemic damage. SCD affects millions of people throughout the world and is particularly common among people whose ancestors come from sub-Saharan Africa, regions in South America, the Caribbean, and Central America, and Mediterranean countries such as Turkey, Greece, and Italy, and many other counties like Saudi Arabia and India. As per latest study released by AMA Research, the Global Hemoglobinopathies market is expected to see growth rate of 5.2%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increasing Prevalence of Hemoglobin Disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E

Market Growth Drivers:
Growing Cases of Hemoglobinopathies, Especially in Regions such as Southeast Asia and Africa and Favorable Government Programs related to Hemoglobinopathies

Challenges:
Insufficient healthcare Infrastructure and Low Levels of Disease Diagnosis and Treatments in Countries like South Africa, and the Mediterranean basin.

Restraints:
Lack of Awareness about these Diseases Leads to Rising in Death to Survival Ratio for Patients Suffering from SCD and Thalassemia

Opportunities:
Rising Research and Development Activities aimed at Developing Novel Therapeutics are Projected Growth of the Market in the Forecast Period

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Abbott Laboratories (United States), Bio-Rad Laboratories, Inc. (United States), Danaher Corporation (United States), Siemens AG (Germany), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Nexcelom Bioscience LLC (United States), Nihon Kohden Corporation (Japan), PerkinElmer Inc. (United States), Apotex Inc. (Canada), CRISPR Therapeutics (Switzerland) and Sysmex Corporation (Japan). The Players having a strong hold in the market are Abbott Laboratories, Bio-Rad Laboratories, Inc., and Danaher Corporation. Additionally, following companies can also be profiled that are part of our coverage like Novartis AG (Switzerland), Medunik USA Inc (United States), Emmaus Medical, Inc (United States), Bristol-Myers Squibb (United States), Alnylam Pharmaceuticals, Inc. (United States), Gamida Cell (Israel), Biogen Inc. (United States), Acceleron Pharma, Inc (United States), Sangamo Therapeutics (United States) and CELGENE CORPORATION (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Hemoglobinopathies market by 2030. Considering Market by Therapy Type, the sub-segment i.e. Blood transfusion will boost the Hemoglobinopathies market. Considering Market by Test Type, the sub-segment i.e. Red Blood Cell (RBC) Count Test will boost the Hemoglobinopathies market. Considering Market by End User, the sub-segment i.e. Diagnostics Laboratories will boost the Hemoglobinopathies market.

Latest Market Insights:
In August 2021, Vertex Pharmaceuticals and Crispr Therapeutics announced a merger to create a new company focused on gene editing therapies, including those for sickle cell disease.

On December 12, 2022, Emma Therapeutics announced the FDA approval of its new drug, called Mycapssa, for the treatment of beta-thalassemia.

What Can be Explored with the Hemoglobinopathies Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hemoglobinopathies Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hemoglobinopathies
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hemoglobinopathies market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hemoglobinopathies market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Hemoglobinopathies Drugs Manufacturers, Research Organizations and Consulting Companies, Related Associations, Organizations, Forums, and Alliances, Government Bodies such as Regulating Authorities and Policymakers, Venture capitalists, Private Equity Firms, and Startup Companies, Distributors and traders and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Thalassemia (Alpha Thalassemia, Beta Thalassemia)
  • Sickle Cell Disease
  • Other Hb Variants Diseases
By Application
  • Blood Testing
  • Genetic Testing
  • Pre-Implantation Genetic Diagnosis (PGD)
  • Others
By Therapy Type
  • Blood transfusion
  • Iron chelation therapy
  • Bone marrow transplant
  • Others

By Test Type
  • Red Blood Cell (RBC) Count Test
  • Genetic Testing
  • Liquid Chromatography (HPLC) Test
  • Hemoglobin Isoelectric (Hb IEF) Focusing
  • Hemoglobin Electrophoresis (Hb ELP) Test
  • Hemoglobin Solubility Test

By End User
  • Diagnostics Laboratories
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Cases of Hemoglobinopathies, Especially in Regions such as Southeast Asia and Africa
      • 3.2.2. Favorable Government Programs related to Hemoglobinopathies
    • 3.3. Market Challenges
      • 3.3.1. Insufficient healthcare Infrastructure and Low Levels of Disease Diagnosis and Treatments in Countries like South Africa, and the Mediterranean basin.
    • 3.4. Market Trends
      • 3.4.1. Increasing Prevalence of Hemoglobin Disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemoglobinopathies, by Type, Application, Therapy Type, Test Type, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemoglobinopathies (Value)
      • 5.2.1. Global Hemoglobinopathies by: Type (Value)
        • 5.2.1.1. Thalassemia (Alpha Thalassemia, Beta Thalassemia)
        • 5.2.1.2. Sickle Cell Disease
        • 5.2.1.3. Other Hb Variants Diseases
      • 5.2.2. Global Hemoglobinopathies by: Application (Value)
        • 5.2.2.1. Blood Testing
        • 5.2.2.2. Genetic Testing
        • 5.2.2.3. Pre-Implantation Genetic Diagnosis (PGD)
        • 5.2.2.4. Others
      • 5.2.3. Global Hemoglobinopathies by: Therapy Type (Value)
        • 5.2.3.1. Blood transfusion
        • 5.2.3.2. Iron chelation therapy
        • 5.2.3.3. Bone marrow transplant
        • 5.2.3.4. Others
      • 5.2.4. Global Hemoglobinopathies by: Test Type (Value)
        • 5.2.4.1. Red Blood Cell (RBC) Count Test
        • 5.2.4.2. Genetic Testing
        • 5.2.4.3. Liquid Chromatography (HPLC) Test
        • 5.2.4.4. Hemoglobin Isoelectric (Hb IEF) Focusing
        • 5.2.4.5. Hemoglobin Electrophoresis (Hb ELP) Test
        • 5.2.4.6. Hemoglobin Solubility Test
      • 5.2.5. Global Hemoglobinopathies by: End User (Value)
        • 5.2.5.1. Diagnostics Laboratories
        • 5.2.5.2. Hospitals
        • 5.2.5.3. Clinics
        • 5.2.5.4. Others
      • 5.2.6. Global Hemoglobinopathies Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Hemoglobinopathies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Nexcelom Bioscience LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nihon Kohden Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PerkinElmer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Apotex Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CRISPR Therapeutics (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sysmex Corporation (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Hemoglobinopathies Sale, by Type, Application, Therapy Type, Test Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemoglobinopathies (Value)
      • 7.2.1. Global Hemoglobinopathies by: Type (Value)
        • 7.2.1.1. Thalassemia (Alpha Thalassemia, Beta Thalassemia)
        • 7.2.1.2. Sickle Cell Disease
        • 7.2.1.3. Other Hb Variants Diseases
      • 7.2.2. Global Hemoglobinopathies by: Application (Value)
        • 7.2.2.1. Blood Testing
        • 7.2.2.2. Genetic Testing
        • 7.2.2.3. Pre-Implantation Genetic Diagnosis (PGD)
        • 7.2.2.4. Others
      • 7.2.3. Global Hemoglobinopathies by: Therapy Type (Value)
        • 7.2.3.1. Blood transfusion
        • 7.2.3.2. Iron chelation therapy
        • 7.2.3.3. Bone marrow transplant
        • 7.2.3.4. Others
      • 7.2.4. Global Hemoglobinopathies by: Test Type (Value)
        • 7.2.4.1. Red Blood Cell (RBC) Count Test
        • 7.2.4.2. Genetic Testing
        • 7.2.4.3. Liquid Chromatography (HPLC) Test
        • 7.2.4.4. Hemoglobin Isoelectric (Hb IEF) Focusing
        • 7.2.4.5. Hemoglobin Electrophoresis (Hb ELP) Test
        • 7.2.4.6. Hemoglobin Solubility Test
      • 7.2.5. Global Hemoglobinopathies by: End User (Value)
        • 7.2.5.1. Diagnostics Laboratories
        • 7.2.5.2. Hospitals
        • 7.2.5.3. Clinics
        • 7.2.5.4. Others
      • 7.2.6. Global Hemoglobinopathies Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemoglobinopathies: by Type(USD Million)
  • Table 2. Hemoglobinopathies Thalassemia (Alpha Thalassemia, Beta Thalassemia) , by Region USD Million (2018-2023)
  • Table 3. Hemoglobinopathies Sickle Cell Disease , by Region USD Million (2018-2023)
  • Table 4. Hemoglobinopathies Other Hb Variants Diseases , by Region USD Million (2018-2023)
  • Table 5. Hemoglobinopathies: by Application(USD Million)
  • Table 6. Hemoglobinopathies Blood Testing , by Region USD Million (2018-2023)
  • Table 7. Hemoglobinopathies Genetic Testing , by Region USD Million (2018-2023)
  • Table 8. Hemoglobinopathies Pre-Implantation Genetic Diagnosis (PGD) , by Region USD Million (2018-2023)
  • Table 9. Hemoglobinopathies Others , by Region USD Million (2018-2023)
  • Table 10. Hemoglobinopathies: by Therapy Type(USD Million)
  • Table 11. Hemoglobinopathies Blood transfusion , by Region USD Million (2018-2023)
  • Table 12. Hemoglobinopathies Iron chelation therapy , by Region USD Million (2018-2023)
  • Table 13. Hemoglobinopathies Bone marrow transplant , by Region USD Million (2018-2023)
  • Table 14. Hemoglobinopathies Others , by Region USD Million (2018-2023)
  • Table 15. Hemoglobinopathies: by Test Type(USD Million)
  • Table 16. Hemoglobinopathies Red Blood Cell (RBC) Count Test , by Region USD Million (2018-2023)
  • Table 17. Hemoglobinopathies Genetic Testing , by Region USD Million (2018-2023)
  • Table 18. Hemoglobinopathies Liquid Chromatography (HPLC) Test , by Region USD Million (2018-2023)
  • Table 19. Hemoglobinopathies Hemoglobin Isoelectric (Hb IEF) Focusing , by Region USD Million (2018-2023)
  • Table 20. Hemoglobinopathies Hemoglobin Electrophoresis (Hb ELP) Test , by Region USD Million (2018-2023)
  • Table 21. Hemoglobinopathies Hemoglobin Solubility Test , by Region USD Million (2018-2023)
  • Table 22. Hemoglobinopathies: by End User(USD Million)
  • Table 23. Hemoglobinopathies Diagnostics Laboratories , by Region USD Million (2018-2023)
  • Table 24. Hemoglobinopathies Hospitals , by Region USD Million (2018-2023)
  • Table 25. Hemoglobinopathies Clinics , by Region USD Million (2018-2023)
  • Table 26. Hemoglobinopathies Others , by Region USD Million (2018-2023)
  • Table 27. South America Hemoglobinopathies, by Country USD Million (2018-2023)
  • Table 28. South America Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 29. South America Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 30. South America Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 31. South America Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 32. South America Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 33. Brazil Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 34. Brazil Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 35. Brazil Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 36. Brazil Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 37. Brazil Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 38. Argentina Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 39. Argentina Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 40. Argentina Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 41. Argentina Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 42. Argentina Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 43. Rest of South America Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 44. Rest of South America Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 45. Rest of South America Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 46. Rest of South America Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 47. Rest of South America Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 48. Asia Pacific Hemoglobinopathies, by Country USD Million (2018-2023)
  • Table 49. Asia Pacific Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 50. Asia Pacific Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 51. Asia Pacific Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 52. Asia Pacific Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 53. Asia Pacific Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 54. China Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 55. China Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 56. China Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 57. China Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 58. China Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 59. Japan Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 60. Japan Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 61. Japan Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 62. Japan Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 63. Japan Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 64. India Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 65. India Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 66. India Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 67. India Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 68. India Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 69. South Korea Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 70. South Korea Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 71. South Korea Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 72. South Korea Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 73. South Korea Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 74. Taiwan Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 75. Taiwan Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 76. Taiwan Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 77. Taiwan Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 78. Taiwan Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 79. Australia Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 80. Australia Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 81. Australia Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 82. Australia Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 83. Australia Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 89. Europe Hemoglobinopathies, by Country USD Million (2018-2023)
  • Table 90. Europe Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 91. Europe Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 92. Europe Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 93. Europe Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 94. Europe Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 95. Germany Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 96. Germany Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 97. Germany Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 98. Germany Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 99. Germany Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 100. France Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 101. France Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 102. France Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 103. France Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 104. France Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 105. Italy Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 106. Italy Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 107. Italy Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 108. Italy Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 109. Italy Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 110. United Kingdom Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 111. United Kingdom Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 112. United Kingdom Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 113. United Kingdom Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 114. United Kingdom Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 115. Netherlands Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 116. Netherlands Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 117. Netherlands Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 118. Netherlands Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 119. Netherlands Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 120. Rest of Europe Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 121. Rest of Europe Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 122. Rest of Europe Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 123. Rest of Europe Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 124. Rest of Europe Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 125. MEA Hemoglobinopathies, by Country USD Million (2018-2023)
  • Table 126. MEA Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 127. MEA Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 128. MEA Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 129. MEA Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 130. MEA Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 131. Middle East Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 132. Middle East Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 133. Middle East Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 134. Middle East Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 135. Middle East Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 136. Africa Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 137. Africa Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 138. Africa Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 139. Africa Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 140. Africa Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 141. North America Hemoglobinopathies, by Country USD Million (2018-2023)
  • Table 142. North America Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 143. North America Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 144. North America Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 145. North America Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 146. North America Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 147. United States Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 148. United States Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 149. United States Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 150. United States Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 151. United States Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 152. Canada Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 153. Canada Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 154. Canada Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 155. Canada Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 156. Canada Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 157. Mexico Hemoglobinopathies, by Type USD Million (2018-2023)
  • Table 158. Mexico Hemoglobinopathies, by Application USD Million (2018-2023)
  • Table 159. Mexico Hemoglobinopathies, by Therapy Type USD Million (2018-2023)
  • Table 160. Mexico Hemoglobinopathies, by Test Type USD Million (2018-2023)
  • Table 161. Mexico Hemoglobinopathies, by End User USD Million (2018-2023)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Hemoglobinopathies: by Type(USD Million)
  • Table 174. Hemoglobinopathies Thalassemia (Alpha Thalassemia, Beta Thalassemia) , by Region USD Million (2025-2030)
  • Table 175. Hemoglobinopathies Sickle Cell Disease , by Region USD Million (2025-2030)
  • Table 176. Hemoglobinopathies Other Hb Variants Diseases , by Region USD Million (2025-2030)
  • Table 177. Hemoglobinopathies: by Application(USD Million)
  • Table 178. Hemoglobinopathies Blood Testing , by Region USD Million (2025-2030)
  • Table 179. Hemoglobinopathies Genetic Testing , by Region USD Million (2025-2030)
  • Table 180. Hemoglobinopathies Pre-Implantation Genetic Diagnosis (PGD) , by Region USD Million (2025-2030)
  • Table 181. Hemoglobinopathies Others , by Region USD Million (2025-2030)
  • Table 182. Hemoglobinopathies: by Therapy Type(USD Million)
  • Table 183. Hemoglobinopathies Blood transfusion , by Region USD Million (2025-2030)
  • Table 184. Hemoglobinopathies Iron chelation therapy , by Region USD Million (2025-2030)
  • Table 185. Hemoglobinopathies Bone marrow transplant , by Region USD Million (2025-2030)
  • Table 186. Hemoglobinopathies Others , by Region USD Million (2025-2030)
  • Table 187. Hemoglobinopathies: by Test Type(USD Million)
  • Table 188. Hemoglobinopathies Red Blood Cell (RBC) Count Test , by Region USD Million (2025-2030)
  • Table 189. Hemoglobinopathies Genetic Testing , by Region USD Million (2025-2030)
  • Table 190. Hemoglobinopathies Liquid Chromatography (HPLC) Test , by Region USD Million (2025-2030)
  • Table 191. Hemoglobinopathies Hemoglobin Isoelectric (Hb IEF) Focusing , by Region USD Million (2025-2030)
  • Table 192. Hemoglobinopathies Hemoglobin Electrophoresis (Hb ELP) Test , by Region USD Million (2025-2030)
  • Table 193. Hemoglobinopathies Hemoglobin Solubility Test , by Region USD Million (2025-2030)
  • Table 194. Hemoglobinopathies: by End User(USD Million)
  • Table 195. Hemoglobinopathies Diagnostics Laboratories , by Region USD Million (2025-2030)
  • Table 196. Hemoglobinopathies Hospitals , by Region USD Million (2025-2030)
  • Table 197. Hemoglobinopathies Clinics , by Region USD Million (2025-2030)
  • Table 198. Hemoglobinopathies Others , by Region USD Million (2025-2030)
  • Table 199. South America Hemoglobinopathies, by Country USD Million (2025-2030)
  • Table 200. South America Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 201. South America Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 202. South America Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 203. South America Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 204. South America Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 205. Brazil Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 206. Brazil Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 207. Brazil Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 208. Brazil Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 209. Brazil Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 210. Argentina Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 211. Argentina Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 212. Argentina Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 213. Argentina Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 214. Argentina Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 215. Rest of South America Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 216. Rest of South America Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 217. Rest of South America Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 218. Rest of South America Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 219. Rest of South America Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 220. Asia Pacific Hemoglobinopathies, by Country USD Million (2025-2030)
  • Table 221. Asia Pacific Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 222. Asia Pacific Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 223. Asia Pacific Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 224. Asia Pacific Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 225. Asia Pacific Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 226. China Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 227. China Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 228. China Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 229. China Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 230. China Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 231. Japan Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 232. Japan Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 233. Japan Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 234. Japan Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 235. Japan Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 236. India Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 237. India Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 238. India Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 239. India Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 240. India Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 241. South Korea Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 242. South Korea Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 243. South Korea Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 244. South Korea Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 245. South Korea Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 246. Taiwan Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 247. Taiwan Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 248. Taiwan Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 249. Taiwan Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 250. Taiwan Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 251. Australia Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 252. Australia Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 253. Australia Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 254. Australia Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 255. Australia Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 256. Rest of Asia-Pacific Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 257. Rest of Asia-Pacific Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 258. Rest of Asia-Pacific Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 259. Rest of Asia-Pacific Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 261. Europe Hemoglobinopathies, by Country USD Million (2025-2030)
  • Table 262. Europe Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 263. Europe Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 264. Europe Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 265. Europe Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 266. Europe Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 267. Germany Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 268. Germany Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 269. Germany Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 270. Germany Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 271. Germany Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 272. France Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 273. France Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 274. France Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 275. France Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 276. France Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 277. Italy Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 278. Italy Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 279. Italy Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 280. Italy Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 281. Italy Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 282. United Kingdom Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 283. United Kingdom Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 284. United Kingdom Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 285. United Kingdom Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 286. United Kingdom Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 287. Netherlands Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 288. Netherlands Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 289. Netherlands Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 290. Netherlands Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 291. Netherlands Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 292. Rest of Europe Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 293. Rest of Europe Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 294. Rest of Europe Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 295. Rest of Europe Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 296. Rest of Europe Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 297. MEA Hemoglobinopathies, by Country USD Million (2025-2030)
  • Table 298. MEA Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 299. MEA Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 300. MEA Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 301. MEA Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 302. MEA Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 303. Middle East Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 304. Middle East Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 305. Middle East Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 306. Middle East Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 307. Middle East Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 308. Africa Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 309. Africa Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 310. Africa Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 311. Africa Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 312. Africa Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 313. North America Hemoglobinopathies, by Country USD Million (2025-2030)
  • Table 314. North America Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 315. North America Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 316. North America Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 317. North America Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 318. North America Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 319. United States Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 320. United States Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 321. United States Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 322. United States Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 323. United States Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 324. Canada Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 325. Canada Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 326. Canada Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 327. Canada Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 328. Canada Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 329. Mexico Hemoglobinopathies, by Type USD Million (2025-2030)
  • Table 330. Mexico Hemoglobinopathies, by Application USD Million (2025-2030)
  • Table 331. Mexico Hemoglobinopathies, by Therapy Type USD Million (2025-2030)
  • Table 332. Mexico Hemoglobinopathies, by Test Type USD Million (2025-2030)
  • Table 333. Mexico Hemoglobinopathies, by End User USD Million (2025-2030)
  • Table 334. Research Programs/Design for This Report
  • Table 335. Key Data Information from Secondary Sources
  • Table 336. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemoglobinopathies: by Type USD Million (2018-2023)
  • Figure 5. Global Hemoglobinopathies: by Application USD Million (2018-2023)
  • Figure 6. Global Hemoglobinopathies: by Therapy Type USD Million (2018-2023)
  • Figure 7. Global Hemoglobinopathies: by Test Type USD Million (2018-2023)
  • Figure 8. Global Hemoglobinopathies: by End User USD Million (2018-2023)
  • Figure 9. South America Hemoglobinopathies Share (%), by Country
  • Figure 10. Asia Pacific Hemoglobinopathies Share (%), by Country
  • Figure 11. Europe Hemoglobinopathies Share (%), by Country
  • Figure 12. MEA Hemoglobinopathies Share (%), by Country
  • Figure 13. North America Hemoglobinopathies Share (%), by Country
  • Figure 14. Global Hemoglobinopathies share by Players 2023 (%)
  • Figure 15. Global Hemoglobinopathies share by Players (Top 3) 2023(%)
  • Figure 16. Global Hemoglobinopathies share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 24. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 26. Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 27. Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China) Revenue: by Geography 2023
  • Figure 28. Nexcelom Bioscience LLC (United States) Revenue, Net Income and Gross profit
  • Figure 29. Nexcelom Bioscience LLC (United States) Revenue: by Geography 2023
  • Figure 30. Nihon Kohden Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Nihon Kohden Corporation (Japan) Revenue: by Geography 2023
  • Figure 32. PerkinElmer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. PerkinElmer Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Apotex Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Apotex Inc. (Canada) Revenue: by Geography 2023
  • Figure 36. CRISPR Therapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. CRISPR Therapeutics (Switzerland) Revenue: by Geography 2023
  • Figure 38. Sysmex Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Sysmex Corporation (Japan) Revenue: by Geography 2023
  • Figure 40. Global Hemoglobinopathies: by Type USD Million (2025-2030)
  • Figure 41. Global Hemoglobinopathies: by Application USD Million (2025-2030)
  • Figure 42. Global Hemoglobinopathies: by Therapy Type USD Million (2025-2030)
  • Figure 43. Global Hemoglobinopathies: by Test Type USD Million (2025-2030)
  • Figure 44. Global Hemoglobinopathies: by End User USD Million (2025-2030)
  • Figure 45. South America Hemoglobinopathies Share (%), by Country
  • Figure 46. Asia Pacific Hemoglobinopathies Share (%), by Country
  • Figure 47. Europe Hemoglobinopathies Share (%), by Country
  • Figure 48. MEA Hemoglobinopathies Share (%), by Country
  • Figure 49. North America Hemoglobinopathies Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Danaher Corporation (United States)
  • Siemens AG (Germany)
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China)
  • Nexcelom Bioscience LLC (United States)
  • Nihon Kohden Corporation (Japan)
  • PerkinElmer Inc. (United States)
  • Apotex Inc. (Canada)
  • CRISPR Therapeutics (Switzerland)
  • Sysmex Corporation (Japan)
Additional players considered in the study are as follows:
Novartis AG (Switzerland) , Medunik USA Inc (United States) , Emmaus Medical, Inc (United States) , Bristol-Myers Squibb (United States) , Alnylam Pharmaceuticals, Inc. (United States) , Gamida Cell (Israel) , Biogen Inc. (United States) , Acceleron Pharma, Inc (United States) , Sangamo Therapeutics (United States) , CELGENE CORPORATION (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 250 Pages 51 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemoglobinopathies Market Quantitative research analysis
Global Hemoglobinopathies Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Hemoglobinopathies market are Abbott Laboratories (United States), Bio-Rad Laboratories, Inc. (United States), Danaher Corporation (United States), Siemens AG (Germany), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Nexcelom Bioscience LLC (United States), Nihon Kohden Corporation (Japan), PerkinElmer Inc. (United States), Apotex Inc. (Canada), CRISPR Therapeutics (Switzerland) and Sysmex Corporation (Japan), to name a few.
"Increasing Prevalence of Hemoglobin Disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E" is seen as one of major influencing trends for Hemoglobinopathies Market during projected period 2023-2030.
Thalassemia (Alpha Thalassemia, Beta Thalassemia) segment in Global market to hold robust market share owing to "Growing Cases of Hemoglobinopathies, Especially in Regions such as Southeast Asia and Africa ".

Know More About Global Hemoglobinopathies Market Report?

Have a Query? Click Here

Other Related Reports

Trigeminal Neuralgia Treatment Comprehensive Study by Type (Medication, Surgery), Application (Hospitals, Clinics, Medical Research Centers), Medicine Type (Anticonvulsant, NSAID's, Opioids, Others),...
$ 3650
Aldosteronism Treatments Comprehensive Study by Drug Type (Aldosterone Receptor Antagonists, Potassium Sparring Diuretics), Indication (Primary Aldosteronism, Secondary Aldosteronism), Distribution C...
$ 3750
Peritonitis Comprehensive Study by Treatment (Antibiotics, Surgery, Kidney Dialysis), Disease Type (Primary Spontaneous Peritonitis, Secondary Peritonitis), End-users (Hospitals, Clinics, Others), Di...
$ 3650
Premenstrual Dysphoric Disorder Comprehensive Study by Treatment (Antidepressants, Contraceptives, Over-the-counter Pain Relievers, Cognitive Therapy, Other Medicines), End-users (Hospitals, Clinics,...
$ 3450
Systemic Mastocytosis Treatments Comprehensive Study by Type (AK-002, BLU-285, Brentuximab Vedotin, Crenolanib Besylate, Cromolyn Sodium, Others), Application (Clinic, Hospital, Homecare, Others), Te...
$ 3650
Allergy Medications Comprehensive Study by Type (Pills, Liquids, Inhalers, Nasal Sprays, Eyedrops, Skin Creams, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmac...
$ 3350